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Objectives: We sought to compare the clinical profile and outcomes of operations
for aortic valve disease and ascending aortic aneurysm in patients treated with aortic
valve replacement and supracoronary replacement of the ascending aorta or com-
posite replacement of the aortic valve and ascending aorta (Bentall operation).
Methods: From 1990 through 2001, 133 patients had aortic valve replacement and
supracoronary replacement of the ascending aorta, and 452 patients had Bentall oper-
ations. Aortic valve replacement and supracoronary replacement of the ascending aorta
was performed in patients who had aortic valve disease and dilation of the ascending aorta,
whereas the Bentall operation was performed in patients with aortic root abnormality and
ascending aortic aneurysm. Mean follow-up was 4.6 3.1 years and was 100% complete.
Results: Patients who had aortic valve replacement and supracoronary replacement
of the ascending aorta were older (61  13 vs 52  16 years, P  .001) and more
likely to have aortic stenosis, coronary artery disease, and mitral valve disease than
those who had Bentall operations. The use of mechanical valves was equal in both
groups (42% for aortic valve replacement and supracoronary replacement of the
ascending aorta and 43% for the Bentall operation). Operative mortality was 5% for
patients undergoing aortic valve replacement and supracoronary replacement of the
ascending aorta and 4% for patients undergoing the Bentall operation (P  .45).
Survival at 10 years was 57%  8% for patients undergoing aortic valve replace-
ment and supracoronary replacement of the ascending aorta and 74%  4% for
patients undergoing the Bentall operation (P  .04), but the type of operation had
no effect on survival. Older age, moderate or severe left ventricular dysfunction,
active endocarditis, previous cardiac surgery, and coronary artery disease were
independent predictors of death. The freedom from reoperation at 10 years was 95%
 5% for patients undergoing aortic valve replacement and supracoronary replace-
ment of the ascending aorta and 94%  3% for patients undergoing the Bentall
operation (P  .18). Reoperations were mostly because of tissue valve failure or
endocarditis. The risk of valve-related complications was the same in both groups.
No patient required reoperation for aortic root aneurysm after having aortic valve
replacement and supracoronary replacement of the ascending aorta.
Conclusions: Aortic valve replacement and supracoronary replacement of the ascending
aorta and the Bentall operation provide comparable long-term results. The Bentall
operation is more appropriate for patients with aortic root abnormality and a dilated
ascending aorta, whereas aortic valve replacement and supracoronary replacement of the
ascending aorta is a perfectly acceptable operation for patients with aortic valve disease,
normal or mildly dilated aortic sinuses, and a dilated ascending aorta.
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In 1968, Bentall and DeBono1 described an opera-tion to treat patients with aortic root aneurysms thatconsisted of composite replacement of the aorticvalve and ascending aorta with reimplantation ofthe coronary arteries by using a conduit containinga mechanical valve. This procedure was modified
somewhat over the years, mostly related to the techniques of
reimplantation of the coronary arteries and of the distal
anastomosis.2 As experience with this operation increased,
its indications were expanded to include patients with other
pathologic processes, such as porcelain aorta and aortic root
abscess, and more recently, it has been used as a technique
for aortic valve replacement when a stentless biologic or
bioprosthetic aortic valve is used.3-5 We have not used this
approach to aortic valve replacement, except when the Ross
procedure is performed.4 If the ascending aorta is dilated
and the aortic root is normal or near normal, we replace the
aortic valve and the supracoronary ascending aorta. More-
over, if the noncoronary sinus of Valsalva is dilated, we
prefer to replace only the noncoronary sinus by tailoring the
supracoronary graft to extend down to the aortic annulus
and leave the coronary arteries undisturbed.
The purpose of this study was to compare the clinical
profile and outcomes of aortic valve replacement combined
with supracoronary replacement of the ascending aorta
(AVRRAA) and composite replacement of the aortic
valve and ascending aorta (Bentall operation) in patients
with aortic valve disease and an ascending aortic aneurysm.
Patients and Methods
From 1990 through 2001, 133 patients underwent AVRRAA,
and 452 patients underwent the Bentall operation performed by 2
surgeons (T.E.D. and C.M.F.) at Toronto General Hospital. Clin-
ical data were entered prospectively into a computerized database.
Patients who had the Ross procedure were excluded unless they
had an ascending aortic aneurysm that required replacement with
a tubular Dacron graft. Table 1 shows the patients’ clinical profile.
Table 2 shows the operative data.
Operations
AVRRAA was performed in patients who had dilated (45 mm)
ascending aortas and normal or minimally dilated aortic sinuses.
However, the noncoronary aortic sinus was dilated or damaged by
dissection, infection, or a previous patch enlargement of the aortic
root in 21 patients, and it was replaced along with the ascending
aorta, but the left and right sinuses and the coronary arteries were
left intact. In these cases the Dacron graft used to replace the
ascending aorta was tailored in such a way as to create a neoaortic
sinus to replace the noncoronary aortic sinus and was secured to
the aortic annulus by using the same sutures used to secure the
prosthetic aortic valve. Other procedures performed in these pa-
tients are listed in Table 2.
The Bentall operation was performed in patients who had aortic
root aneurysm (311 patients), active or healed aortic root abscess
(33 patients), calcified aortic sinuses (32 patients), previously
replaced aortic root (28 patients), previously replaced aortic valve
with patch enlargement of the aortic annulus (17 patients), need for
correction of patient-prosthesis mismatch (19 patients), and com-
plex aortic annulus-root problems (12 patients). These patients also
had dilated ascending aortas. The aortic root was replaced with a
biologic or prosthetic valved conduit, and the coronary arteries
were reimplanted by using the button technique. In 15 patients who
TABLE 1. Clinical profile of patients
AVR  RAA
Bentall
operation
P
value
No. of patients 133 452
Age, y (mean  SD) 61.4 13.4 52.3 16.3 .001
Sex
Male 97 (73) 346 (77)
Female 36 (27) 106 (23) .4
NYHA functional class .001
Class 1 6 (5) 78 (17)
Class 2 47 (35) 151 (33)
Class 3 51 (38) 109 (24)
Class 4 29 (22) 114 (25)
Left ventricular ejection fraction .73
59% 41 (31) 151 (34)
40%-59% 68 (51) 205 (46)
20%-39% 22 (17) 86 (19)
20% 2 (1) 6 (1)
Aortic valve lesion .001
Stenosis 64 (48) 105 (23)
Insufficiency 46 (34) 230 (51)
Mixed 22 (16) 93 (20)
Not recorded 1 (1) 24 (5)
Timing of operation .17
Elective 103 (78) 312 (69)
Urgent 27 (20) 105 (23)
Emergency 3 (2) 34 (8)
Endocarditis .08
Remote 2 (2) 20 (4)
Active 2 (2) 8 (3)
Aortic root abscess 1 (1) 20 (4)
Previous cardiac surgery 30 (23) 165 (37) .003
Previous aortic valve surgery 22 (17) 136 (30) .003
Marfan syndrome 0 23 (6) .001
Coronary artery disease 44 (33) 95 (21) .001
Mitral valve disease 25 (21) 34 (8) .03
Aortic dissection
Acute 3 (2) 26 (6) .1
Chronic 2 (1) 13 (3) .4
Recent myocardial infarction
(30 d)
0 5 (1) .50
Congestive heart failure 58 (44) 56 (35) .06
Preoperative renal failure 2 (2) 6 (1) .88
Chronic obstructive lung
disease
6 (5) 11 (2) .24
Peripheral vascular disease 10 (8) 7 (2) .001
Diabetes mellitus 9 (7) 26 (6) .70
Hypertension 55 (41) 151 (34) .17
Percentages are shown in parentheses.
AVR  RAA, Aortic valve replacement combined with supracoronary
replacement of the ascending aorta; Bentall operation, aortic root replace-
ment; NYHA, New York Heart Association.
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had a previous aortic root replacement, one or both coronary
arteries had to be extended with a short segment of Dacron graft or,
in cases of active endocarditis, with a saphenous vein graft before
they could be connected to the valved conduit. Other procedures
are listed on Table 2.
With the exception of cases of active infective endocarditis
when an aortic homograft was preferentially used, patients chose
the type of heart valve implanted.
Follow-up
The referring cardiologists followed the patients at annual intervals
or more often if needed, and the information contained in their
consultation letter was extracted and entered into our database. An
annual echocardiogram was obtained for most patients. Our re-
search personnel contacted all patients periodically through ques-
tionnaires and telephone calls. Postoperative events were compiled
and analyzed according to the “Guidelines for reporting morbidity
and mortality after cardiac valvular operations.”6 The follow-up
for this study was closed on December 31, 2002; extended from 0
to 13 years (mean of 4.6  3.1 years); and was 100% complete.
Both operations were performed throughout the period of obser-
vation, and the duration of follow-up was similar in both groups
(4.9 3.2 years for the AVRRAA group and 4.4 2.8 years for
the Bentall group, P  .3).
Statistical Analysis
Statistical analysis was done with SAS 8.1 software (SAS Institute,
Cary, NC). Discrete patient variables were compared by using the
contingency table method or the Fisher exact test. The means of
continuous variables were compared by using Student t tests.
Survival and freedom from morbid events were compared by using
the Kaplan-Meier method. Independent predictors were deter-
mined by means of Cox multivariable analysis, with backward
elimination of nonsignificant determinants.
Results
Table 1 shows that patients who underwent AVRRAA
were older and had more aortic stenosis, coronary artery
disease, and mitral valve disease than those who underwent
the Bentall operation, and those undergoing the Bentall
operation, who had more aortic insufficiency, included all
patients with Marfan syndrome and more patients who had
previous aortic valve operations. Table 2 shows that the
proportions of patients who had mechanical valves were
similar between the 2 groups, but the types of bioprosthetic
and biologic valves were different. The AVRRAA group
had more stented bioprostheses, whereas the Bentall group
had more homografts and stentless porcine bioprostheses.
Table 3 shows the operative mortality and morbidity.
The operative mortality was 5% for the AVRRAA group
TABLE 2. Operative data
AVR  RAA
Bentall
operation P value
Aortic valve pathology .001
Rheumatic 11 (8) 5 (1)
Tricuspid calcific 21 (16) 24 (5)
Bicuspid 56 (42) 175 (38)
Other congenital 3 (2) 12 (3)
Aortic annulus ectasia 3 (2) 58 (13)
Aortic dissection 6 (4) 38 (8)
Prosthetic dysfunction 20 (15) 89 (20)
Miscellaneous 7 (5) 36 (8)
Not recorded 11 (8) 40 (9)
Type of heart valve implanted .001
Mechanical 56 (42) 196 (43)
Aortic homograft 0 49 (11)
Pulmonary autograft 4 (3) 19 (4)
Stentless porcine 4 (3) 145 (32)
Stented bioprosthesis 69 (52) 43 (10)
Coronary artery bypass 48 (36) 98 (22) .001
Mitral valve repair-replacement 25 (21) 41 (9) .03
Tricuspid valve repair 2 (2) 5 (1) .65
Pulmonary valve replacement 4 (3) 19 (4) .42
Replacement of aortic arch 13 (10) 12 (3) .05
Circulatory arrest 45 (34) 92 (20) .001
Aortic crossclamp time (min)* 92 31 106 36 .001
CPB time (min)* 120 42 135 49 .001
ICU stay (d)* 2.3 4.3 1.9 4.5 .35
Hospital stay (d)* 11.2 14.6 10.7 15.2 .74
Percentages are shown in parentheses.
AVR  RAA, Aortic valve replacement combined with supracoronary
replacement of the ascending aorta; Bentall operation, aortic root replace-
ment; CPB, cardiopulmonary bypass; ICU, intensive care unit.
*Values are expressed as means  SD.
TABLE 3. Operative mortality and morbidity
AVR  RAA
Bentall
operation P value
Operative deaths 7 (5%) 18 (4%) .45
Causes of operative death
Cardiac failure 3 7
Sudden death 0 5
Multiorgan failure 0 2
Sepsis 2 0
Hemorrhage 1 0
Respiratory failure 1 0
Stroke 0 2
Ruptured thoracic aneurysm 0 1
Sternal infection 0 1
Operative morbidity*
Perioperative MI 1 5
Low output syndrome 11 38
Intra-aortic balloon pump 7 30
Perioperative stroke 6 11
Assisted ventilation 48 h 12 18
Renal failure 3 8
Re-exploration of mediastinum
Bleeding 10 27
Tamponade 5 8
Wound dehiscence 0 1
Sternal infection 3 0
Other 1 2
AVR  RAA, Aortic valve replacement combined with supracoronary
replacement of the ascending aorta; Bentall operation, aortic root replace-
ment; MI, myocardial infarction.
*Includes patients who died.
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was 4% for the Bentall group (P  .45). The type of
operation (AVRRAA or the Bentall operation) had no
effect on operative mortality. Advanced age, New York
Heart Association functional class 4, urgent-emergency op-
erations, and the need for circulatory arrest were indepen-
dent predictors of operative mortality.
Late Survival
There were 24 late deaths in the AVRRAA group and 45
in the Bentall group (Table 4). Figure 1 shows the survival
at 10 years, which was lower in the AVRRAA group than
in the Bentall group (57%  8% vs 74%  4%, P  .04),
but Cox regression analysis showed that the type of opera-
tion was not an independent predictor of late death (Table
5). Older age, left ventricular dysfunction (ejection fraction
of 40%), active endocarditis, previous cardiac surgery,
and coronary artery disease were the only independent
predictors of late death.
Thromboembolic Complications
There were 6 thromboembolic events in the AVRRAA
group, none of which were fatal, and 25 thromboembolic
events in the Bentall group, 4 of which were fatal. The
freedom from thromboembolism at 10 years was 96% 2%
in the AVRRAA group and 92%  2% in the Bentall
group (P  .4). The type of prosthetic aortic valve was
univariately associated with thromboembolism complica-
tions: at 10 years, the freedom from thromboembolism was
98%  2% for aortic homografts, 88%  3% for mechan-
ical valves, and 97%  2% for bioprosthetic valves (P 
.008).
Prosthetic Valve Endocarditis
Nine patients had prosthetic valve endocarditis: 1 in the
AVRRAA group and 8 in the Bentall group. Five patients
had early (6 months) and 4 had late infections. Four
patients who had undergone the Bentall operation under-
went reoperation and survived. The remaining patients were
treated with antibiotics alone because they were deemed
inoperable, and 3 died (1 in the AVRRAA group and 2 in
the Bentall group). The freedom from prosthetic valve en-
docarditis at 10 years was 86%  13% in the AVRRAA
group and 96%  2% in the Bentall group (P  .5). The
type of prosthetic heart valve had no effect on the risk of
endocarditis: the freedom from endocarditis at 10 years was
91%  7% with aortic homografts, 94%  5% with me-
chanical valves, and 99%  1% with bioprosthetic valves
(P  .7).
Anticoagulation-related Hemorrhage
Of 242 patients receiving oral anticoagulants (208 with
mechanical valves and 34 with tissue valves), 30 patients
had at least one episode of bleeding: 10 minor and 20 major.
All patients with major bleeding required hospitalization,
and 2 died. The freedom from bleeding at 10 years was 85%
 3% for all patients receiving oral anticoagulants, 94% 
3% for the AVRRAA group, and 83%  4% for the
Bentall group (P  .16).
Structural Valve Failure
One patient in the AVRRAA group had bioprosthetic
structural valve failure but did not undergo reoperation
TABLE 4. Causes of death
AVR 
RAA
Bentall
operation
Total no. of deaths 31 63
Operative deaths 7 18
Late deaths 24 45
Sudden death 3 4
Myocardial infarction 3 3
Congestive heart failure 5 6
Stroke 1 4
Prosthetic valve endocarditis 1 2
Anticoagulation-related bleeding 1 1
Structural valve deterioration 1 0
Ruptured aneurysm 1 2
False aneurysm of coronary button 0 1
Noncardiovascular death 8 22
AVR  RAA, Aortic valve replacement combined with replacement of the
supracoronary ascending aorta; Bentall operation, aortic root replace-
ment.
Figure 1. Long-term survival.
TABLE 5. Independent predictors of death
Variable
Hazard
ratio
95% Confidence
limits
P
value
Age by 5-y increments 1.05 1.03-1.07 .001
Ejection fraction 20%-39% 1.90 1.51-3.14 .01
Ejection fraction 20% 3.50 1.07-11.37 .04
Active endocarditis 2.88 1.48-5.60 .002
Previous cardiac surgery 2.12 1.37-3.28 .001
Coronary artery disease 1.55 1.01-2.40 .049
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because of advanced age and numerous comorbid condi-
tions. Five patients in the Bentall group had structural valve
failure: 4 aortic homografts and 1 xenograft. All 5 under-
went successful reoperation.
Reoperations
Twelve patients underwent reoperations: 1 in the
AVRRAA group for prosthetic valve dehiscence and 11
in the Bentall group (4 for endocarditis, 5 for prosthetic
valve failure, and 2 for valve-patch dehiscence in patients
who had complex reconstruction of the left ventricular
outflow tract). There were no operative deaths among pa-
tients who required reoperations. Figure 2 shows the free-
dom from reoperation. It was similar in the 2 groups.
Valve-related Mortality and Morbidity
Freedom from valve-related mortality and morbidity at 10
years was 80% in the AVRRAA group and 83% in the
Bentall group (P  .8).
No patient in the AVRRAA group had aortic root
aneurysm, and there were no reoperations or verified deaths
caused by aortic root aneurysm in these patients.
Late Functional Class
At the last follow-up contact, 101 patients who underwent
AVRRAA were alive, and 63% were in New York Heart
Association functional class 1, 25% were in class 2, 10%
were in class 3, and 2% were in class 4. Of 378 patients who
underwent the Bentall operation, 71% were in class 1, 19%
were in class 2, and 10% were in class 3.
Discussion
This study showed that the outcomes of AVRRAA were
similar to those of the Bentall operation in patients with
aortic valve disease and ascending aortic aneurysms. The
fact that no patient who underwent AVRRAA had aortic
root aneurysm is an indication that the patients were cor-
rectly selected for this operation.
The clinical profiles of our patients who underwent
AVRRAA or the Bentall operation were different than
those reported by Yun and colleagues7 from Stanford Uni-
versity. In that series the patients who had the Bentall
operation were 10 years younger than ours; 44% had
Marfan syndrome, and 34% had aortic dissection. The lower
incidences of Marfan syndrome and aortic dissection in our
series are likely a reflection on differences in surgical man-
agement of these diseases. Most patients with Marfan syn-
drome have aortic valve–sparing operations in our institu-
tion.8 Similarly, those with aortic dissection often have their
native aortic valve preserved.9 These are the reasons why
only 6% of patients who underwent the Bentall operation
had Marfan syndrome and only 7.5% of all patients had
aortic dissection in our series. The study from Stanford
spanned more than 3 decades, and consequently, the oper-
ative mortality was higher than ours at 15% for AVRRAA
and 14% for the Bentall operation.7 For the above reasons,
it might be inappropriate to compare the clinical outcomes
of these 2 series. However, their conclusions were the same
as ours: AVRRAA and the Bentall operation provided
similar clinical outcomes, and the type of operation had no
effect on operative and long-term survival.7 Moreover,
AVRRAA was an appropriate operation for patients with
aortic valve disease and ascending aortic aneurysm, as long
as the aortic sinuses were normal or minimally dilated.7
In a report by Houe¨l and colleagues10 from France, the
type of operation had no effect on long-term survival, but
AVRRAA was associated with more aortic wall compli-
cations (aortic root dilation and false aneurysms) than the
Bentall operation. However, AVRRAA was performed in
patients with Marfan syndrome and others with aortic root
aneurysm.10 We observed none of the complications de-
scribed in that report, but there was no patient with Marfan
syndrome or aortic root aneurysm in the AVRRAA group
in our series.
Although the risk of development of aortic root aneu-
rysm might be eliminated by proper patient selection for
AVRRAA, these patients, unlike those who undergo the
Bentall operation, are exposed to a risk of prosthetic valve
dehiscence, as we observed in one patient in our series. This
risk, however, should be weighed against the hazards of
coronary artery reimplantation and other problems related to
aortic root replacement.7,11,12 Intraoperative bleeding and
kinking can be difficult to manage, and late problems, such
as false or true aneurysm of the arterial button, coronary
artery, or both, as well as periaortic fistulas, can also oc-
cur.11,12 To minimize the problems related with reimplan-
tation of the coronary arteries, Cabrol and associates13 de-
scribed an operative procedure whereby the 2 coronary
arteries were connected together by a Dacron graft, which
was then sutured to the valved conduit in a side-to-side
fashion. This procedure has been associated with more
Figure 2. Freedom from reoperation.
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problems than the arterial button technique and has been
abandoned by most surgeons.14 However, in cases of aortic
root rereplacement, it is not always feasible to reattach the
coronary arteries directly to the valved conduit, and an
extension of the coronary artery with a short segment of
Dacron graft or saphenous vein might be necessary.15
Early reports indicate that prosthetic conduits containing
mechanical valves were preferentially used for aortic root
replacement to decrease the probability of reopera-
tion.2,13,16,17 However, because of a variety of factors, such
as increased experience with reoperations, development of
newer bioprosthetic heart valves, and better appreciation of
the problems related with anticoagulation, recent reports
suggest a trend toward the use of biologic and bioprosthetic
heart valves in these patients.3,5,7,18 The risk of reoperation
has to be weighed against the risk of life-long anticoagula-
tion with warfarin sodium and, as shown in this report, an
increased risk of thromboembolic complications. In certain
conditions, however, such as in aortic root abscess, the use
of an aortic valve homograft might be preferable because it
appears to increase the probability of cure of the infection.19
Finally, pulmonary autografts have also been used in certain
patients with aortic valve disease and ascending aortic an-
eurysm.20 This operation might be inappropriate for patients
with aortic root aneurysm because the risk of dilation of the
pulmonary autograft is increased when it is subjected to
systemic pressures because it often has the same histologic
abnormality as the aortic root.21,22 However, if the aortic
root is not dilated and the aneurysm is limited to the as-
cending aorta, it might be reasonable to use a pulmonary
autograft to replace the aortic root and a tubular Dacron
graft to replace the ascending aorta.20
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